| 3.11 0.02 (0.65%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.78 | 1-year : | 4.13 |
| Resists | First : | 3.24 | Second : | 3.53 |
| Pivot price | 3.24  |
|||
| Supports | First : | 2.76 | Second : | 2.29 |
| MAs | MA(5) : | 3.1 |
MA(20) : | 3.26 |
| MA(100) : | 7.5 |
MA(250) : | 10.4 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 14.7 |
D(3) : | 15.8 |
| RSI | RSI(14): 27.5 |
|||
| 52-week | High : | 15.08 | Low : | 2.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EMBC ] has closed above bottom band by 24.3%. Bollinger Bands are 78.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.14 - 3.15 | 3.15 - 3.16 |
| Low: | 3 - 3.02 | 3.02 - 3.03 |
| Close: | 3.09 - 3.11 | 3.11 - 3.13 |
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Fri, 19 Jun 2026
Class Action Lawsuit Filed: Embecta Corp. (EMBC) – Join by August 17, 2026 – Contact Levi & Korsinsky - ACCESS Newswire
Fri, 19 Jun 2026
Embecta Corp. (EMBC) Faces Securities Class Action for - GlobeNewswire
Thu, 18 Jun 2026
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit - GuruFocus
Thu, 18 Jun 2026
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit - Loudoun Times-Mirror
Thu, 18 Jun 2026
Rosen Law Firm Urges Embecta Corp. (NASDAQ: EMBC) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
Thu, 18 Jun 2026
BTIG Sticks to Its Hold Rating for Embecta Corporation (EMBC) - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 59 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 100.5 (%) |
| Shares Short | 7,410 (K) |
| Shares Short P.Month | 6,050 (K) |
| EPS | 1.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -10.56 |
| Profit Margin | 10.7 % |
| Operating Margin | 19.3 % |
| Return on Assets (ttm) | 16.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -14.4 % |
| Gross Profit (p.s.) | 10.87 |
| Sales Per Share | 17.52 |
| EBITDA (p.s.) | 5.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 214 (M) |
| Levered Free Cash Flow | 196 (M) |
| PE Ratio | 1.64 |
| PEG Ratio | 0 |
| Price to Book value | -0.3 |
| Price to Sales | 0.17 |
| Price to Cash Flow | 0.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|